PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
 
BMC Cancer. 2012; 12: 187.
Published online May 22, 2012. doi:  10.1186/1471-2407-12-187
PMCID: PMC3404914
ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy
Jong-Mu Sun,#1 Ji-Youn Sung,#2 Se Hoon Park,1 Ghee Young Kwon,2 Byong Chang Jeong,3 Seong Il Seo,3 Seong Soo Jeon,3 Hyun Moo Lee,3 Jisuk Jo,4 Han Yong Choi,3 and Ho Yeong Limcorresponding author1
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
2Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
3Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
4Cancer Research Institute, Research Institute for Future Medicine, Samsung Medical Center, Seoul, South Korea
corresponding authorCorresponding author.
#Contributed equally.
Jong-Mu Sun: tntntn3/at/gmail.com; Ji-Youn Sung: Jiyoun.sung/at/samsung.com; Se Hoon Park: sh1767.park/at/samsung.com; Ghee Young Kwon: geeo.kwon/at/samsung.com; Byong Chang Jeong: bc2.jung/at/samsung.com; Seong Il Seo: seongil.seo/at/samsung.com; Seong Soo Jeon: seongsoo.jeon/at/samsung.com; Hyun Moo Lee: hyunmoo.lee/at/samsung.com; Jisuk Jo: callian/at/paran.com; Han Yong Choi: hanyong.choi/at/samsung.com; Ho Yeong Lim: hoy.lim/at/samsung.com
Received November 26, 2011; Accepted May 22, 2012.
Abstract
Background
The role of adjuvant chemotherapy and the value of molecular biomarkers in bladder cancer have not been determined. We aimed to assess the predictive and prognostic values of excision repair cross-complementation 1 (ERCC1) in identifying appropriate patients who may potentially benefit from adjuvant chemotherapy for bladder cancer.
Methods
A retrospective analysis was performed on 93 patients with completely resected transitional cell carcinoma of the bladder. ERCC1 expression was assessed by immunohistochemistry. ERCC1 expression was analyzed in 57 patients treated with adjuvant gemcitabine plus cisplatin chemotherapy and 36 who were not treated.
Results
Among 93 patients, ERCC1 expression was positive in 54 (58.1%) and negative in 39 (41.9%). ERCC1 positivity was significantly associated with longer survival (adjusted hazard ratio for death, 0.12, 95% confidence interval [CI] 0.014-0.99; P = 0.049) in the group without adjuvant chemotherapy while ERCC1 positivity was associated with shorter survival among patients who have received adjuvant chemotherapy (adjusted hazard ratio for death, 2.64; 95% CI 1.01-6.85; P = 0.047). Therefore, clinical benefit from adjuvant chemotherapy was associated with ERCC1 negativity as measured by overall survival (test for interaction, P = 0.034) and by disease-free survival (test for interaction, P = 0.20).
Conclusions
Among patients with completely resected transitional cell carcinoma of the bladder, those with ERCC1-negative tumors seemed to benefit more from adjuvant gemcitabine plus cisplatin chemotherapy than those with ERCC1-positive tumors. Future prospective, randomized studies are warranted to confirm our findings.
Articles from BMC Cancer are provided here courtesy of
BioMed Central